Related Experiment Video
Updated: May 25, 2025
09:08
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021
5.3K
Molecular Hydrogen Therapy for SLE-PAH: Case Report on Immune Marker Modulation
Ting-Hao Tu1, Jeng-Wei Lu2,3,4, Chun-Hsien Wu5
1Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, R.O.C.
In Vivo (Athens, Greece)
|February 26, 2025
Summary
Molecular hydrogen therapy shows promise for treating pulmonary arterial hypertension in systemic lupus erythematosus patients. This adjuvant treatment stabilized a patient with severe symptoms and improved immune markers without adverse effects.
Area of Science:
- Immunology
- Cardiology
- Pulmonology
Background:
- Systemic lupus erythematosus-associated pulmonary arterial hypertension (SLE-PAH) is a severe condition.
- Standard treatments for SLE-PAH often prove insufficient.
- There is a critical need for novel therapeutic strategies.
Purpose of the Study:
- To evaluate the efficacy of molecular hydrogen therapy in a patient with SLE-PAH.
- To assess its impact on decompensated right-sided heart failure.
- To explore its effects on immune cell populations.
Main Methods:
- A case study of a 51-year-old female with SLE-PAH.
- Adjuvant molecular hydrogen therapy administered via daily capsules.
- Monitoring of clinical symptoms and immune cell subsets (Tr1, Treg, B cells, etc.).
Main Results:
- Molecular hydrogen therapy stabilized the patient's clinical symptoms.
- An increase in Tr1 cells and a decrease in Treg, B cell subsets, marginal cell, and plasma cell percentages were observed.
- No adverse effects or complications were reported.
Conclusions:
- Molecular hydrogen therapy may be a potential treatment for SLE-PAH with decompensated right-sided heart failure.
- The therapy demonstrated an ability to modulate specific immune markers.
- Further research is warranted to confirm these therapeutic benefits.
